| Literature DB >> 34557650 |
Pranav Nayak B1, Nathani Minaz1, Khadar Pasha1.
Abstract
Diabetic neuropathy is a disorder that affects various regions of the nervous system and there is no specific treatment available for it. This study evaluated the protective effect of molsidomine in diabetic neuropathy in rats. Diabetes was induced in male Wistar rats by administrating streptozotocin (52 mg/kg ip). Diabetic rats were treated with molsidomine 5 mg/kg po and 10 mg/kg po. After 8 weeks of treatment, motor coordination, mechanical allodynia, mechanical hyperalgesia, nerve conduction velocity, and glycosylated hemoglobin were assessed. Thereafter, animals were killed and the sciatic nerve was isolated for measurement of reduced glutathione and lipid peroxidation, and histopathological analysis. Treatment with molsidomine significantly improved motor coordination, paw withdrawal threshold, mechanical threshold, and nerve conduction velocity. Furthermore, molsidomine treatment also reduced malondialdehyde levels and prevented depletion of reduced glutathione in the sciatic nerve homogenate. Histopathology revealed that molsidomine treatment maintained normal architecture of the sciatic nerve. The results of our study strengthen the alternative use of molsidomine in diabetic neuropathy.Entities:
Keywords: Wistar rats; diabetic neuropathy; molsidomine; streptozotocin
Mesh:
Substances:
Year: 2021 PMID: 34557650 PMCID: PMC8446713 DOI: 10.1002/ame2.12162
Source DB: PubMed Journal: Animal Model Exp Med ISSN: 2576-2095
FIGURE 1Effect of molsidomine treatment on motor coordination in diabetic rats. Values are represented as mean ± SEM (n = 6). One‐way ANOVA followed by Dunnet's test. ***P < .001 vs diabetic control group. DC, diabetic control; Mol, molsidomine; NC, normal control
FIGURE 2Effect of molsidomine on mechanical threshold and paw withdrawal threshold in diabetic rats. Values are represented as mean ± SEM (n = 6). One‐way ANOVA followed by Dunnet's test. ***P < .001 vs diabetic control group. DC, diabetic control; Mol, molsidomine; NC, normal control
FIGURE 3Effect of molsidomine on sciatic nerve conduction velocity in diabetic rats. Values are represented as mean ± SEM (n = 6). One‐way ANOVA followed by Dunnet's test. ***P < .001 vs diabetic control group. DC, diabetic control; Mol, molsidomine; NC, normal control
Effect of molsidomine on glycosylated Hb, GSH, and MDA levels in diabetic rats
| Sl. No. | Groups | % glycosylated Hb | GSH (mcg/mg) | MDA (nmol/mg) |
|---|---|---|---|---|
| 1. | Normal control | 2.76 ± 0.16 | 104.2 ± 02.32 | 3.28 ± 0.17 |
| 2. | Diabetic control | 14.71 ± 0.19 | 62.89 ± 1.99 | 7.44 ± 0.55 |
| 3. | Diabetic + MOL (5mg/kg) | 10.53 ± 0.93 | 73.77 ± 0.93 | 5.06 ± 0.04 |
| 4. | Diabetic + MOL (10mg/kg) | 6.58 ± 0.28 | 89.94 ± 0.87 | 3.74 ± 0.16 |
Values are represented as mean ± SEM (n = 6). One‐way ANOVA followed by Dunnet's test.
Abbreviations: GSH, glutathione; Hb, hemoglobin; mcg, microgram; MDA, malondialdehyde, mg, milligram; MOL, molsidomine; nmol, nanomole.
P < .001 vs diabetic control group.
FIGURE 4Histopathology of the sciatic nerve (10X). A, Sciatic nerve of normal rats showing elongated Schwann cell nuclei and longitudinally oriented axons with myelin sheath. B, Sciatic nerve of diabetic rats has shown mainly axonal swelling observed with intact myelin. C, Sciatic nerve of molsidomine (5 mg) treated rats showing nuclear degeneration in focal areas with few fiber arrangements. D, Sciatic nerve of molsidomine (10 mg) treated rats showing nuclear degeneration in few areas with few fiber arrangements